<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00788424</url>
  </required_header>
  <id_info>
    <org_study_id>#72REV00</org_study_id>
    <nct_id>NCT00788424</nct_id>
  </id_info>
  <brief_title>Topical Application of AS101 for the Treatment of Psoriasis</brief_title>
  <official_title>Study of Topical Application of AS101 for the Treatment of Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioMAS Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioMAS Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol relates to a phase II randomized double blind, placebo controlled study of the
      AS101 topical application for the treatment of mild to moderate Psoriasis.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Sponsor's considerations
  </why_stopped>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the percentege of patients in which modified PASI (mPASI) score reduction of more than 66% from Baseline whithin 12-week treatment period is achieved</measure>
    <time_frame>12 weeks treatment and 3 month follow up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The main secondary endpoints are to evaluate safety, tolerability of topical AS010 treatment and long term remission of psoriasis.</measure>
    <time_frame>12 weeks treatment and 3 month follow up</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Mild to Moderate Psoriasis</condition>
  <arm_group>
    <arm_group_label>AS101 Cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twice daily topical application of AS101 cream on the psoriatic lesions for approx. 12 weeks is expected to clear the treated area.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twice daily topical application on the psoriatic lesions for 8 weeks will serve as control group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AS101 Cream</intervention_name>
    <description>4% AS101 Cream or Placebo cream, twice a day for 12 weeks</description>
    <arm_group_label>AS101 Cream</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient have a diagnosed mild to moderate stable plaque type psoriasis (less than 10%
             of body skin surface).

          2. Patient must be 18-70 years of age.

          3. General health must be adequate to allow for compliance with the requirements of this
             protocol.

          4. Patient or his/her legal guardian must sign an informed consent form prior to study
             participation.

          5. Patient must be able and willing to comply with all protocol requirements.

        Exclusion Criteria:

          1. Patients who are mentally disabled or are otherwise unable to provide fully informed
             consent.

          2. Pregnant or breast-feeding females.

          3. Patients with evidence of an infection in the targeted zones.

          4. Patients with known sensitivity to any of the drug components.

          5. Patients treated by systemic anti psoriatic medications within one month prior to the
             initial treatment with the AS101, or topical anti psoriatic preparations within two
             weeks prior to the initial treatment with the AS101.

          6. Patient with psoriatic arthritis.

          7. Patients taking immunosuppressive drugs.

          8. Immunocompromised patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arie Ingbar, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah Medical Organization</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hadassah Medical Organization</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2008</study_first_submitted>
  <study_first_submitted_qc>November 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2008</study_first_posted>
  <last_update_submitted>July 22, 2015</last_update_submitted>
  <last_update_submitted_qc>July 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AS101 Psoriasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ammonium trichloro(dioxoethylene-O,O'-)tellurate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

